Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
dc.conference.date | SEP 16-21, 2021 | |
dc.conference.title | Congress of the European-Society-for-Medical-Oncology (ESMO) | |
dc.contributor.author | Shu, C. A. | |
dc.contributor.author | Goto, K. | |
dc.contributor.author | Ohe, Y. | |
dc.contributor.author | Besse, B. | |
dc.contributor.author | Park, K. | |
dc.contributor.author | Wang, Y. | |
dc.contributor.author | Griesinger, F. | |
dc.contributor.author | Yang, J. C-H. | |
dc.contributor.author | Felip, E. | |
dc.contributor.author | Sanborn, R. E. | |
dc.contributor.author | Caro, R. Bernabe | |
dc.contributor.author | Bauml, J. M. | |
dc.contributor.author | Chen, J. | |
dc.contributor.author | Fennema, E. | |
dc.contributor.author | Mahoney, J. | |
dc.contributor.author | Trani, L. | |
dc.contributor.author | Knoblauch, R. E. | |
dc.contributor.author | Thayu, M. | |
dc.contributor.author | Cho, B. C. | |
dc.contributor.authoraffiliation | [Shu, C. A.] Columbia Univ, Med Ctr, Med, New York, NY USA | |
dc.contributor.authoraffiliation | [Goto, K.] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan | |
dc.contributor.authoraffiliation | [Ohe, Y.] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan | |
dc.contributor.authoraffiliation | [Besse, B.] Gustave Roussy, Canc Med, Villejuif, France | |
dc.contributor.authoraffiliation | [Park, K.] Sungkyunkwan Univ, Samsung Med Ctr, Med, Sch Med, Seoul, South Korea | |
dc.contributor.authoraffiliation | [Wang, Y.] Sichuan Univ, West China Hosp, Inst Drug Clin Trial, Chengdu, Peoples R China | |
dc.contributor.authoraffiliation | [Wang, Y.] Sichuan Univ, West China Hosp, Dept Thorac Canc, Chengdu, Peoples R China | |
dc.contributor.authoraffiliation | [Wang, Y.] Collaborat Innovat Ctr, Chengdu, Peoples R China | |
dc.contributor.authoraffiliation | [Griesinger, F.] Carl von Ossietzky Univ Oldenburg, Hematol & Oncol, Pius Hosp, Oldenburg, Germany | |
dc.contributor.authoraffiliation | [Yang, J. C-H.] Natl Taiwan Univ, Med Oncol, Ctr Canc, Taipei, Taiwan | |
dc.contributor.authoraffiliation | [Felip, E.] Vall Hebron Univ Hosp, Oncol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Sanborn, R. E.] Earle Chiles Res Inst, Providence Canc Inst, Med Oncol, Portland, OR USA | |
dc.contributor.authoraffiliation | [Caro, R. Bernabe] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain | |
dc.contributor.authoraffiliation | [Bauml, J. M.] Univ Penn, Perelman Sch Med, Med, Philadelphia, PA USA | |
dc.contributor.authoraffiliation | [Chen, J.] Janssen R&D, Clin Biostat, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Fennema, E.] Janssen R&D, Oncol, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Trani, L.] Janssen R&D, Oncol, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Knoblauch, R. E.] Janssen R&D, Oncol, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Thayu, M.] Janssen R&D, Oncol, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Mahoney, J.] Janssen R&D, Clin Oncol, Spring House, PA USA | |
dc.contributor.authoraffiliation | [Cho, B. C.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea | |
dc.contributor.funder | Janssen | |
dc.date.accessioned | 2025-01-07T15:32:57Z | |
dc.date.available | 2025-01-07T15:32:57Z | |
dc.date.issued | 2021-09-21 | |
dc.identifier.doi | 10.1016/j.annonc.2021.08.1798 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | https://doi.org/10.1016/j.annonc.2021.08.1798 | |
dc.identifier.uri | https://hdl.handle.net/10668/27229 | |
dc.identifier.wosID | 700527702212 | |
dc.issue.number | 5 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen del Rocío | |
dc.page.number | S952-S953 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 32 | |
dc.wostype | Meeting Abstract |